Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034924.xml
Download PDF
Nuklearmedizin 2015; 54(01): 01-11
DOI: 10.1055/s-0037-1616604
DOI: 10.1055/s-0037-1616604
DGN-Handlungsempfehlung
Peptidrezeptor-Radionuklidtherapie Somatostatinrezeptor- exprimierender Tumore
DGN-Leitlinie (S1)[*] Article in several languages: deutsch | EnglishFurther Information
Publication History
20 November 2014
Publication Date:
10 January 2018 (online)
Zusammenfassung
Diese Handlungsempfehlung soll eine Grundlage für die Qualitätssicherung der Peptid - rezeptor-Radionuklidtherapie (PRRT) von Patienten mit Somatostatinrezeptor-exprimierenden Tumoren schaffen, die zurzeit in Deutschland bei fehlenden gleichwertigen oder besseren Therapiealternativen im Rahmen eines individuellen Heilversuches erfolgt. Sie wurde interdisziplinär erarbeitet und enthält neben Definition, allgemeiner Zielsetzung und klinischen Hintergrundinformationen Angaben zu Indikationen und Kontraindikationen der PRRT. Im Mittelpunkt stehen die Anforderungen, die an das Behandlungszentrum gestellt werden, wie die enge Zusammenarbeit der an der Behandlung beteiligten Fachgebiete. Weiterhin wird spezifiziert, welche Untersuchungsbefunde vor der Therapie vorliegen müssen und wie die PRRT technisch und organisatorisch durchzuführen ist. Nach der Behandlung ist eine langfristige Nachsorge/Kontrolle der therapierten Patienten – u. a. zur Gewinnung onkologischer Qualitätsparameter – unabdingbar. Die gesamte Behandlung einschließlich der Nachsorge muss in enger Abstimmung und Zusammenarbeit der beteiligten Fachdisziplinen erfolgen, wobei in der Regel die Empfehlung zur PRRT durch ein multidisziplinäres Tumorboard erfolgen sollte.
-
Literatur
- 1 Salazar R, Wiedenmann B, Rindi G, Ruszniewski P. ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: an update. Neuroendocrinology 2012; 95: 71-73.
- 2 Öberg K, Hellman P, Ferolla P, Papotti M. Group obotEGW. Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23: vii120-vii123.
- 3 Öberg K, Knigge U, Kwekkeboom D, Perren A. Group obotEGW. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23: vii124-vii130.
- 4 Zaknun JJ, Bodei L, Mueller-Brand J. et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2013; 40: 800-816.
- 5 International Atomic Energy Agency. (Ed) Practical Guidance on Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumours. www-pub.iaea.org/MTCD/Publications/PDF/P1560_web.pdf
- 6 Reubi JC, Schar JC, Waser B. et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27: 273-282.
- 7 Anlauf M, Gerlach P, Raffel A. et al. Neuroendokrine Neoplasien des gastroenteropankreatischen Systems. Der Onkologe 2011; 17: 572-582.
- 8 HÖrsch D, Grabowski P, Schneider CP. et al. Current treatment options for neuroendocrine tumors. Drugs Today (Barc) 2011; 47: 773-786.
- 9 Rinke A, Muller HH, Schade-Brittinger C. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663.
- 10 Raymond E, Dahan L, Raoul JL. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513.
- 11 Yao JC, Shah MH, Ito T. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
- 12 Kwekkeboom DJ, de Herder WW, Kam BL. et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2130.
- 13 Imhof A, Brunner P, Marincek N. et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011; 29: 2416-2423.
- 14 Bushnell Jr. DL, O'Dorisio TM, O'Dorisio MS. et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010; 28: 1652-1659.
- 15 Khan S, Krenning EP, van Essen M. et al. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med 2011; 52: 1361-1368.
- 16 Caplin M, Sundin A, Nillson O. et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology 2012; 95: 88-97.
- 17 Delle Fave G, Kwekkeboom DJ, Van Cutsem E. et al. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology 2012; 95: 74-87.
- 18 Falconi M, Bartsch DK, Eriksson B. et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2012; 95: 120-134.
- 19 Jensen RT, Cadiot G, Brandi ML. et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012; 95: 98-119.
- 20 Kwekkeboom DJ, Krenning EP, Lebtahi R. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 2009; 90: 220-226.
- 21 Pape UF, Perren A, Niederle B. et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012; 95: 135-156.
- 22 Pavel M, Baudin E, Couvelard A. et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95: 157-176.
- 23 Baum RP, Kulkarni HR. THERANOSTICS: From molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy - The Bad Berka Experience. Theranostics 2012; 2: 437-447.
- 24 Kwekkeboom DJ, Teunissen JJ, Bakker WH. et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23: 2754-2762.
- 25 Boy C, Heusner TA, Poeppel TD. et al. 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging 2011; 38: 1224-1236.
- 26 Campana D, Ambrosini V, Pezzilli R. et al. Standardized uptake values of 68Ga-DOTANOC PET: A promising prognostic tool in neuroendocrine tumors. J Nucl Med 2010; 51: 353-359.
- 27 Ezziddin S, Opitz M, Attassi M. et al. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2011; 38: 459-466.
- 28 Bodei L, Cremonesi M, Ferrari M. et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008; 35: 1847-1856.
- 29 Bartolomei M, Bodei L, De Cicco C. et al. Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging 2009; 36: 1407-1416.
- 30 Ferrari M, Cremonesi M, Bartolomei M. et al. Dosimetric model for locoregional treatments of brain tumors with 90Y-conjugates: clinical application with 90Y-DOTATOC. J Nucl Med 2006; 47: 105-112.
- 31 Kwekkeboom DJ, Mueller-Brand J, Paganelli G. et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005; 46 (Suppl 1) 62S-66S.
- 32 Valkema R, Pauwels SA, Kvols LK. et al. Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA(0),Tyr(3)-octreotide and 177Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005; 46 (Suppl 1) 83S-91S.
- 33 van Essen M, Krenning EP, Kam BL. et al. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2008; 35: 743-748.
- 34 Rolleman EJ, Melis M, Valkema R. et al. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging 2010; 37: 1018-1031.
- 35 Vegt E, de Jong M, Wetzels JF. et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 2010; 51: 1049-1058.
- 36 B. Braun Melsungen AG: Gelafundin 4 % InfusionslÖsung – Fachinformation. Juli 2008
- 37 Kratochwil C, Giesel FL, Lopez-Benitez R. et al. Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res 2010; 16: 2899-2905.
- 38 Baum RP, Kulkarni HR, Carreras C. Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms. Semin Nucl Med 2012; 42: 190-207.
- 39 Villard L, Romer A, Marincek N. et al. Cohort study of somatostatin-based radiopeptide therapy with [90Y-DOTA]-TOC versus [90Y-DOTA]-TOC plus [177Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 2012; 30: 1100-1106.
- 40 Cremonesi M, Ferrari M, Bodei L. et al. Dosimetry in Peptide radionuclide receptor therapy: a review. J Nucl Med 2006; 47: 1467-1475.
- 41 Cremonesi M, Ferrari M, Zoboli S. et al. Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with 90Y-DOTATOC. Eur J Nucl Med 1999; 26: 877-886.
- 42 Kwekkeboom DJ, Bakker WH, Kooij PP. et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med 2001; 28: 1319-1325.
- 43 Forrer F, Uusijarvi H, Waldherr C. et al. A comparison of 111In-DOTATOC and 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004; 31: 1257-1262.
- 44 Wehrmann C, Senftleben S, Zachert C. et al. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm 2007; 22: 406-416.
- 45 Rodrigues M, Traub-Weidinger T, Li S. et al. Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2006; 33: 532-540.
- 46 Forrer F, Krenning EP, Kooij PP. et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 2009; 36: 1138-1146.
- 47 Forster GJ, Engelbach MJ, Brockmann JJ. et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of 86Y-DOTATOC and 111In-DTPA-octreotide. Eur J Nucl Med 2001; 28: 1743-1750.
- 48 Helisch A, Forster GJ, Reber H. et al. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004; 31: 1386-1392.
- 49 Menda Y, O'Dorisio MS, Kao S. et al. Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors. J Nucl Med 2010; 51: 1524-1531.
- 50 Kwekkeboom DJ, Kooij PP, Bakker WH. et al. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med 1999; 40: 762-767.
- 51 Hindorf C, Chittenden S, Causer L. et al. Dosimetry for 90Y-DOTATOC therapies in patients with neuroendocrine tumors. Cancer Biother Radiopharm 2007; 22: 130-135.
- 52 Sandstrom M, Garske U, Granberg D. et al. Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging 2010; 37: 212-225.
- 53 Jamar F, Barone R, Mathieu I. et al. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003; 30: 510-518.
- 54 Arnold R, Chen YJ, Costa F. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 2009; 90: 227-233.
- 55 Ruf J, Schiefer J, Furth C. et al. 68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol. J Nucl Med 2011; 52: 697-704.